Skip to main content
. Author manuscript; available in PMC: 2018 Jan 8.
Published in final edited form as: Vaccine. 2017 May 27;36(3):347–354. doi: 10.1016/j.vaccine.2017.05.012

Table 4.

Risk of aseptic meningitis following mumps-containing vaccination and risk of immune thrombocytopenic purpura (ITP) following measles-containing vaccination; overall and by vaccine strain

SCRI analyses

Mumps vaccine strain1 Eligible confirmed aseptic meningitis cases2 Follow-up (days) Relative incidence (IRR)
Event in risk period (8-35 days) Event in non-risk period (43-84 days) Median (P25-P75) Unadjusted (95% CI) Adjusted 95% CI
Overall 35 5 85 (85, 85) 10.9 (4.2- 27.8) 10.8 (4.0-29.2)
Overall3 22 3 85 (85, 85) 11.7 (3.5-39.3) 12.4 (3.1-49.1)
Hoshino/Leningrad-Zagreb/UrabeAm9 27 2 85 (85, 85) 20.3 (4.8-85.2) Non-estimable
Hoshino/Leningrad-Zagreb/UrabeAm9* 14 0 85 (85, 85) Non-estimable Non-estimable
Leningrad-Zagreb 7 1 85 (85, 85) 10.8 (1.3-87.4) 6.4 (0.3-124.4)
RIT 4385/Jeryl Lynn (Level B) 0 1 85 (85, 85) Non-estimable Non-estimable

Measles vaccine strain Eligible confirmed ITP cases1 Follow-up (days) Relative incidence (IRR)
Event in risk period (8-35 days) Event in non-risk period (43-84 days) Median (P25-P75) Unadjusted 95% CI Adjusted 95% CI

Overall 36 12 85 (70, 85) 5.0 (2.5-9.7) 5.6 (2.7-11.9)
Overall3 36 8 85 (70, 85) 7.7 (3.5-17.3) 9.1 (3.7-22.3)
AIK-C/ Edmonston-Zagreb /Schwarz 2 5 85 (85, 85) 0.51 (0.10-2.54) 0.54 (0.08-3.55)
Edmonston-Zagreb 7 1 85 (67, 85) 11.1 (1.4-90.3) 8.4 (0.7-100.3)
Enders´ Edmonston 11 3 85 (43, 85) 8.5 (1.9-38.1) 28.7 (1.9-443.5)
Schwarz 14 1 85 (76, 85) 20.7 (2.7-157.6) Non-estimable
Shanghai-191 0 1 85 (85, 85) Non-estimable Non-estimable
1

There were no cases within days 8-35 or days 43-84 following first dose vaccination with mumps strains S79 or Urabe Am9.

2

The remaining cases occurred during the washout periods (days 1-7, days 36-42 following vaccination)

3

Excluding cases from Iran-01 since this site did not provide exact vaccination dates